Elin Jäger/LinkedIn
Aug 24, 2026, 13:19
Elin Jäger: NNHF First-Half 2026 Programme Report
Elin Jäger, Senior Vice President, Chief of Staff and Head of CEO Office, Corporate Strategy and Sustainability at Novo Nordisk, shared a post on LinkedIn:
“What does progress look like?
As a member of the Novo Nordisk Haemophilia & Haemoglobinopathies Foundation Council, I’ve seen it’s rarely one big moment – it’s built locally, over time and together.
A few highlights from the NNHF First-Half 2026 Programme Report:
- Mozambique: mor than 180 healthcare professionals trained in haemophilia care
- Nigeria: 74 stakeholders united to launch a Technical Working Group on inherited blood disorders
- Across regions: from East Africa to the Caribbean, partners are sharing expertise across borders.
What does lasting progress in haemophilia care look like where you are?”
Stay updated with Hemostasis Today.
-
Aug 24, 2026, 15:15Jim Hoffman: Could Targeting NETosis Reduce Long-Term Risk After STEMI?
-
Aug 24, 2026, 14:58Danny Hsu: Rethinking Bleeding Risk in Patients on Anticoagulation
-
Aug 24, 2026, 14:18The Way to a Safer Workplace for People With Bleeding Disorders – EHC
-
Aug 24, 2026, 14:09Stuart Andrew: NHS Blood and Transplant Strengthening the Blood Supply
-
Aug 24, 2026, 14:05Edward Lee Carter: Anticoagulation Stewardship is Moving From Recommendation to Measurement
-
Aug 24, 2026, 13:58Meera Chitlur: Transforming Care for Heavy Menstrual Bleeding at Children’s Hospital of Michigan
-
Aug 24, 2026, 13:49Heghine Khachatryan: Prepartum Acquired Hemophilia A and the Challenge of Maternal and Neonatal Bleeding
-
Aug 24, 2026, 13:44Neeraj Songara: Therapeutic Plasma Exchange in Severe Guillain–Barré Syndrome
-
Aug 24, 2026, 13:42Pall T. Onundarson: The Role of Measuring Treatment Effect in Optimizing DOAC and Warfarin Therapy